Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $10.3 million.

  • Theravance Biopharma's Accumulated Expenses rose 3172.66% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 3172.66%. This contributed to the annual value of $7.0 million for FY2024, which is 893.99% up from last year.
  • Latest data reveals that Theravance Biopharma reported Accumulated Expenses of $10.3 million as of Q3 2025, which was up 3172.66% from $7.3 million recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Accumulated Expenses peaked at $15.6 million during Q1 2021, and registered a low of $4.5 million during Q1 2024.
  • In the last 5 years, Theravance Biopharma's Accumulated Expenses had a median value of $7.3 million in 2025 and averaged $8.3 million.
  • Per our database at Business Quant, Theravance Biopharma's Accumulated Expenses plummeted by 7166.25% in 2021 and then soared by 3172.66% in 2025.
  • Theravance Biopharma's Accumulated Expenses (Quarter) stood at $12.8 million in 2021, then fell by 19.4% to $10.3 million in 2022, then plummeted by 37.53% to $6.4 million in 2023, then increased by 8.94% to $7.0 million in 2024, then soared by 47.17% to $10.3 million in 2025.
  • Its last three reported values are $10.3 million in Q3 2025, $7.3 million for Q2 2025, and $5.4 million during Q1 2025.